Trials / Recruiting
RecruitingNCT04862052
Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis
OPtimal TrEatment for CoroNary Drug Eluting Stent In-Stent Restenosis: Paclitaxel Versus Sirolimus Coated Balloons Versus Everolimus Eluting Stents - the OPEN ISR Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Semmelweis University Heart and Vascular Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this open label, randomized study is to compare the safety and efficacy of three different methods to handle coronary drug eluting stent (DES) in-stent restenosis (ISR). These are the: * Magic Touch - sirolimus coated balloon * Emperor - paclitaxel and dextran coated balloon * Xience - chromium-cobalt everolimus eluting stent
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Intravascular management of prior implanted coronary drug eluting stent restenosis | Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management. |
Timeline
- Start date
- 2021-04-26
- Primary completion
- 2025-01-01
- Completion
- 2025-01-01
- First posted
- 2021-04-27
- Last updated
- 2024-11-22
Locations
2 sites across 1 country: Hungary
Source: ClinicalTrials.gov record NCT04862052. Inclusion in this directory is not an endorsement.